Genetic screening no better than traditional risk factors for predicting type 2 diabetes
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP, the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Congenital fibrinogen deficiency is a rare, potentially life-threatening bleeding disorder that affects an estimated one person per million,
Full Post: CSL Behring receives FDA approval of RiaSTAP
Screening for a panel of gene variants associated with the risk for type 2 diabetes can identify adults at risk for the disorder but is not significantly better than assessment based on traditional risk factors such as weight, blood pressure and blood sugar levels.
A multi-institutional research team, led by a Massachusetts General Hospital (MGH) physician, reports their analysis of data from the Framingham Heart Study in the November 20 New England Journal of Medicine .
“Although we did confirm that the more risk-associated gene variants you inherit, the greater your risk for developing type 2 diabetes, genetic risk prediction for diabetes is still in its infancy,” says James Meigs, MD, MPH, of the MGH General Medicine Unit, the study’s lead author. “As additional risk genes are discovered, the value of genetic screening is likely to improve. But with our current knowledge, the measurements your physician makes in a standard checkup tell what you need to know about your type 2 diabetes risk, and genetics doesn’t tell you much more.”
It is well known that having a close relative with type 2 diabetes significantly increases the risk of developing the disorder. Meigs explains that it has been assumed that genetic transmission was largely responsible for that increased risk, although it is also well known that behaviors underlying lifestyle-based factors, such as diet and exercise, are learned in family settings. Recent genetic studies have identified 18 gene variants that appear to increase the risk for type 2 diabetes, and the current study was designed to investigate how valuable screening for those variants would be to predict future risk.
The researchers analyzed data from the Framingham Offspring Study, which follows a group of adult children of participants in the original Framingham Heart Study to evaluate risk factors for the development of cardiovascular disease, including diabetes. Genotyping for 18 diabetes-associated variants was conducted on blood samples from more than 2,700 Framingham Study participants. Comprehensive information on diabetes-associated risk factors and outcomes was available for 2,377 of the genotyped participants, 255 of whom developed type 2 diabetes during 28 years of followup.
Each participant was assigned a genotype score, based on the number of risk-associated gene copies inherited. The researchers compared the predictive value of genotype score to that of family history alone or of physiological risk factors. While the genotype score confirmed that inheriting more risk-associated alleles increased type 2 diabetes risk, the ability of the genotype score to discriminate those who did not develop diabetes from those who did was not significantly better than family history or individual risk factors.
“With the current state of knowledge, the genotype score doesn’t help us sort out who is at elevated risk any better than measures like weight. We may eventually find out that those individuals without known risk factors who still develop type 2 diabetes have more diabetes-risk genes, once we know what more of those genes are,” Meigs says. “One potential way a genotype score could be clinically valuable is if knowledge of elevated genetic risk would make patients more willing to make lifestyle changes that we know will reduce risk. That’s something we’re hoping to investigate in the near future.” Meigs is an associate professor of Medicine at Harvard Medical School.
Abnormalities in genes that repair mistakes in DNA replication may help identify people who are at high risk of developing pancreatic cancer, a research team from The University of Texas M. D. Anderson Cancer Center reports in the Jan. 15 issue of Clinical Cancer Research. Defects in these critical DNA repair genes may act alone
Full Post: Defects in critical DNA repair genes may predict pancreatic cancer risk
Patients with type 2 diabetes who have poor glycemic control and a certain genetic variation have an increased risk of coronary artery disease, according to a study in the November 26 issue of JAMA, the Journal of the American Medical Association. Among the known risk factors for cardiovascular disease, diabetes mellitus ranks as one of
Full Post: Genetic variation for persons with diabetes linked to greater risk of coronary artery disease
An international research team has identified 11 novel locations in the human genome where common variations appear to influence cholesterol or triglyceride levels, bringing the total number of lipid-associated genes to 30. While major mutations in some of these genes have been known to underlie rare lipid metabolism disorders, it is becoming apparent that common
Full Post: Discovery of 11 new gene sites that influence cholesterol or triglyceride levels
A third of Americans with diabetes do not know that they have it, and many more who have prediabetic conditions are unaware that they are at risk. A University of Missouri researcher has created a clinical tool to identify those at highest risk for having undetected hyperglycemia, impaired fasting glucose (IFG) and undiagnosed diabetes. If
Full Post: New clinical tool to identify those at highest risk for having undetected hyperglycemia
Scientists have identified 12 new genes that are somewhat strange bedfellows: Some link gallstones and blood cholesterol levels, others link melatonin and sleep patterns to small increases in glucose levels and larger jumps in the risk of diabetes. While these associations are surprising, all the genes are potential new drug targets and some of them
Full Post: Scientists find 12 new genes with potential as drug targets